|
KMID : 1141720210090010037
|
|
폐쇄성폐질환
2021 Volume.9 No. 1 p.37 ~ p.41
|
|
|
When Is Dual Bronchodilator Therapy Indicated as Initial Treatment?
|
|
Kang Ji-Eun
|
|
|
Abstract
|
|
|
|
Bronchodilators are the most essential pharmacotherapy in the management of chronic obstructive pulmonary disease. Fixed-dose combinations of long-acting beta-2 agonist and long-acting muscarinic antagonist (dual therapy) have been demonstrated more effective than monotherapy in improving forced expiratory volume at 1 s (FEV1), reducing St. George’s Respiratory Questionnaire (SGRQ) total scores and preventing acute exacerbations. However, there is currently a lack of evidence on clinical indicators suggesting which patients should start treatment with dual therapy. Although it is generally accepted that patients with frequent exacerbations and a high symptom burden may benefit from early dual therapy, indications for dual therapy slightly differ between guidelines. Future research is required to guide the decision on the early start of dual therapy.
|
|
|
KEYWORD
|
|
|
Chronic obstructive pulmonary disease, Long-acting beta-2 agonist, Long-acting muscarinic antagonist, Dual bronchodilator treatment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|